# Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma

> **NCT01913691** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Merkel Cell Carcinoma

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT01913691
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-07-09
- **Primary completion:** 2014-02-03
- **Final completion:** 2014-02-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01913691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01913691, "Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01913691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*